USFDA decision on Eisai, Biogen Alzheimer's drug due in January Ruchika Sharma6 July 2022 4:30 AM GMTEisai in March downsized its role in Aduhelm, but remains the leader in the 50-50 partnership's lecanemab program.
Biogen CEO to step down as drugmaker pulls back from Alzheimer's drug Aduhelm Ruchika Sharma4 May 2022 6:00 AM GMTBiogen said on Tuesday it was looking at "substantially" eliminating commercial infrastructure related to Aduhelm and plans for more cost cuts, in...
Biogen Alzheimer's drug: Former FDA adviser calls for wider probe into approval Ruchika Sharma21 July 2021 8:30 AM GMTNew Delhi: A federal probe of the U.S. Food and Drug Administration's approval of a controversial new Alzheimer's disease drug should look into why...
